Co-provided by Albert Einstein College of Medicine and Integrity Continuing Education, Inc.
Supported by an educational grant from Novartis Pharmaceuticals Corporation
Plaque psoriasis is an immune-mediated, chronic, inflammatory condition that represents a significant physical and psychological health burden to those afflicted with the disease. It is extremely diverse in its clinical presentation and is associated with a wide range of comorbidities, posing a significant challenge to healthcare providers with regard to both diagnosis and treatment. Despite the availability of a wide range of therapeutic options and highly detailed guidelines for the care of patients with psoriasis, current evidence indicates that evaluation and treatment is inadequate and, furthermore, that patient satisfaction is very low. Educational interventions are required to aid clinicians in their efforts to provide better management of the disease by choosing optimal treatments tailored to the individual characteristics of each patient.
This educational initiative has been designed for rheumatologists, dermatologists, internal medicine physicians, and primary care physicians.
At the conclusion of this activity, participants should be better able to:
Identify evidence-based strategies for the treatment of patients with psoriasis
Summarize current evidence in support of the efficacy and safety of new and emerging systemic and biologic therapies for the treatment of plaque psoriasis
Describe an approach to complete disease management that takes into consideration increased cardiovascular risk and other comorbidities in patients with psoriasis
Conflict Of Interest Disclosure Policy
The "Conflict of Interest Statement" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical or equipment company.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device not yet approved for use in the United States.
*The ACCME defines a Commercial Interest as an entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interest.
Alan Menter, MD Chair and Program Director, Dermatology Baylor University Medical Center Principal Faculty Texas A&M Health Science Center Dallas, TX
Dr. Menter discloses the following: Consulting Fee: AbbVie, Afecta, Amgen, Avillion, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly, Galderma, Janssen Biotech, Inc., LEO Pharma, Menlo, Novartis Pharmaceuticals Corporation, OrthoDermatologics, Pfizer, Promius Speakers’ Bureau: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma, OrthoDermatologics, Promius Contracted Research: AbbVie, Amgen, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene, Dermira, Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron
April Armstrong, MD, MPH Associate Dean for Clinical Research Keck School of Medicine University of Southern California Los Angeles, CA
Dr. Armstrong discloses the following: Consulting Fee: AbbVie, Eli Lilly, Janssen Biotech, Inc., Modernizing Medicine, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron, Sanofi, Science 37, Valeant Pharmaceuticals, LLC
Accredited Provider Disclosure
Einstein Peer Reviewers Chaim Putterman, MD (Content Reviewer) Professor, Department of Medicine (Rheumatology) Professor, Department of Microbiology & Immunology Albert Einstein College of Medicine Montefiore Medical Center Chief, Division of Rheumatology Bronx, NY
Dr. Putterman does not have any real or apparent conflicts of interest to report.
Victor B. Hatcher, PhD (CME Reviewer) Associate Dean Professor, Department of Medicine Professor, Department of Microbiology Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY
Dr. Hatcher does not have any real or apparent conflicts of interest to report.
CCME staff, Albert Einstein College of Medicine, have no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity will discuss the investigational, unapproved, or off-label use of Certolizumab Pegol, Tildrakizumab, Risankizumab, and CF 101 in the treatment of plaque psoriasis. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Presented by Albert Einstein College of Medicine and Integrity Continuing Education, Inc.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine or Integrity Continuing Education, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
There are no fees for participating and receiving CME credit for this activity. During the period of February 5, 2018 through February 5, 2019, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A certificate will be issued upon receipt of a completed activity evaluation form and a successful post-test score of 70% or higher. Your online certificate will also be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact 718-920-6674.